A person accused of participating in a federal drug conspiracy may discover that prosecutors want to attribute drugs handled, transported, or sold by someone else. The amount may include transactions the person did not attend, controlled substances the person never possessed, or sales completed by other alleged conspiracy participants.
Another person’s drug quantity can affect a federal sentencing calculation, but attribution is not automatic. Under the Federal Sentencing Guidelines, the court must examine the scope of the criminal activity the defendant agreed to undertake, if the other person’s conduct furthered that activity, and if the conduct was reasonably foreseeable in connection with it.
Determining drug quantity in a federal conspiracy case requires a defendant-specific analysis. Being charged as part of a broad conspiracy does not automatically make each defendant responsible for every controlled substance associated with the alleged organization. The Guidelines expressly separate the scope of the complete conspiracy from the narrower scope of the activity an individual defendant agreed to undertake.
Drug quantity can affect the statutory sentencing range, the advisory guideline calculation, plea discussions, and the arguments presented at sentencing.
Why Drug Quantity Matters in a Federal Drug Case
Title 21 U.S.C. § 841 prohibits conduct that includes manufacturing, distributing, dispensing, and possessing controlled substances with intent to distribute. Its penalty provisions address the type and quantity of the controlled substance, serious bodily injury or death, qualifying prior convictions, and other facts connected to the offense.
A federal controlled-substance conspiracy may be charged under 21 U.S.C. § 846. That statute provides that a person who attempts or conspires to commit a controlled-substance offense is subject to the penalties prescribed for the underlying offense.
Drug quantity may affect two distinct parts of a federal sentencing analysis.
The first is the statutory sentencing range. A drug type or quantity that increases the authorized statutory maximum or mandatory minimum must be established through a qualifying admission or jury finding, subject to the rules governing prior convictions. The Supreme Court has reaffirmed that facts increasing the prescribed statutory range fall within the jury-trial rule established by Apprendi v. New Jersey and Alleyne v. United States.
The second is the advisory guideline calculation. Section 2D1.1 of the Federal Sentencing Guidelines assigns base offense levels using the type and quantity of the controlled substance. Although the Guidelines are advisory, a federal court must calculate and consider the applicable guideline range as part of sentencing.
These are separate questions. A quantity considered as relevant conduct for the advisory guideline calculation does not, by itself, expand the statutory maximum or mandatory minimum authorized by the conviction, plea, or jury findings.
Does a Conspiracy Charge Make Every Defendant Responsible for Every Drug?
No. The conduct needed to establish participation in a conspiracy is broader than the conduct that may be attributed to an individual defendant for guideline sentencing purposes.
In United States v. McReynolds, the Sixth Circuit explained that the scope of relevant conduct in a drug-conspiracy sentencing analysis is “significantly narrower” than the conduct needed to establish a conspiracy conviction. The court emphasized that jointly undertaken criminal activity is not necessarily equal to the complete conspiracy and that relevant conduct may differ from one participant to another.
A defendant may know that other people are distributing controlled substances without agreeing to participate in all of their transactions. Knowledge of a larger operation does not, standing alone, make every transaction part of the defendant’s jointly undertaken activity.
The sentencing court must identify the scope of the individual defendant’s agreement before assigning quantities from transactions completed by someone else. A court cannot attribute a conspiracy-wide drug amount without findings connecting that quantity to the defendant under the relevant-conduct rules.
People facing this issue can learn more about Davis & Hoss’s federal drug violations defense services.
What Does Relevant Conduct Mean in a Federal Drug Case?
Relevant conduct is the conduct used to determine the offense level under the Federal Sentencing Guidelines. It can include acts committed directly by the defendant and certain acts committed by other participants.
For conduct committed by another person, U.S.S.G. § 1B1.3(a)(1)(B) requires three findings. The conduct must have been within the scope of the criminal activity the defendant agreed to undertake, in furtherance of that criminal activity, and reasonably foreseeable in connection with it.
All three requirements must be satisfied. Conduct outside the scope of the defendant’s agreement does not become relevant conduct merely because the defendant knew about it or could anticipate that it might occur.
The court must begin with the scope of the defendant’s agreement. It should not begin with the total amount attributed to the complete conspiracy and then assume that the same figure applies to each person charged.
What Activity Did the Defendant Agree to Undertake?
The scope inquiry focuses on the criminal activity the individual defendant agreed to carry out with other people.
Evidence bearing on that question may include recorded conversations, text messages, payment records, deliveries, meetings, travel records, financial arrangements, assigned responsibilities, surveillance, and statements attributed to the defendant.
Consider a person accused of agreeing to complete one delivery. Evidence that the person knew the supplier had additional customers would not automatically establish an agreement to participate in every transaction conducted by that supplier.
The commentary to § 1B1.3 illustrates this distinction. When a person agrees to participate in one drug delivery, the person is accountable for the agreed delivery. The person is not automatically accountable for unrelated sales made by another participant before or after that transaction.
The Guidelines also distinguish independent dealers who obtain drugs from a shared source from participants who pool resources, divide responsibilities, or share profits as part of a common undertaking. A shared supplier, standing alone, does not make each customer responsible for every other customer’s transactions.
A limited task, short participation period, or connection to one shipment may support an argument that the defendant’s agreement was narrower than the complete conspiracy alleged in the indictment. The result depends on the evidence defining the agreement.
Did the Other Person’s Conduct Further the Agreed Activity?
After identifying the scope of the defendant’s agreement, the court must examine if the other participant’s conduct advanced that agreed criminal activity.
Suppose two people allegedly agreed to receive and distribute one identified shipment. Actions taken by either participant to receive, store, transport, or distribute that shipment may further the shared undertaking.
The analysis may be different when another person completes a separate transaction for a different customer, during a different period, or for an independent purpose outside the defendant’s agreement.
A transaction does not become relevant conduct merely because both people were named in the same indictment, knew the same supplier, or dealt with the same type of controlled substance.
Was the Other Person’s Conduct Reasonably Foreseeable?
The third requirement concerns reasonable foreseeability. The court examines if the other participant’s conduct was reasonably foreseeable in connection with the criminal activity the defendant agreed to undertake.
Foreseeability cannot replace the scope requirement. Prosecutors cannot establish relevant conduct solely by arguing that the defendant could have predicted that additional drug sales would occur.
The transaction must first fall within the scope of the defendant’s agreement and further the jointly undertaken activity. The court then examines reasonable foreseeability.
A person may recognize that a supplier conducts other transactions without agreeing to share responsibility for the quantities involved in those separate transactions.
Quantities Directly Involving the Defendant
A separate relevant-conduct provision applies to the defendant’s own qualifying acts.
Under § 1B1.3(a)(1)(A), a defendant may be accountable for conduct the defendant committed, aided, abetted, counseled, commanded, induced, procured, or willfully caused. In a controlled-substance case, this may include quantities the defendant personally handled and quantities connected to acts the defendant assisted or directed.
The reasonable-foreseeability limitation applies to qualifying conduct committed by other participants under § 1B1.3(a)(1)(B). It does not limit quantities connected to the defendant’s own conduct under subsection (a)(1)(A).
Direct involvement does not eliminate factual disputes. Questions may remain about drug identity, weight, purity, ownership, laboratory testing, chain of custody, or the reliability of the evidence connecting a substance to the defendant.
Can Drugs Distributed Before a Person Joined the Conspiracy Be Counted?
The commentary to § 1B1.3 states that conduct committed by conspiracy participants before the defendant joined the conspiracy is not included as that defendant’s relevant conduct under the jointly undertaken activity rule, even when the defendant knew about the earlier conduct.
The date of the defendant’s alleged participation may therefore become an important sentencing issue. Evidence may include dated communications, payments, introductions, meetings, deliveries, surveillance records, and travel records.
The starting date alleged for the complete conspiracy does not automatically become the starting date for each person charged.
This limitation concerns guideline relevant conduct. It does not create a broad rule excluding earlier activity from every evidentiary or sentencing issue.
Can Uncharged Transactions Affect the Guideline Calculation?
An uncharged transaction may affect a guideline calculation when it qualifies under the applicable relevant-conduct provision. The correct analysis depends on whose conduct is at issue.
When the government relies on conduct committed by another participant, § 1B1.3(a)(1)(B) requires findings concerning scope, furtherance, and reasonable foreseeability. The fact that another transaction involved the same controlled substance or occurred during the same investigation does not remove those requirements.
A defendant’s own additional transactions may fall under § 1B1.3(a)(2) when they were part of the same course of conduct or common scheme or plan and the applicable offense is subject to grouping under § 3D1.2(d).
These are separate paths to relevant conduct. The same-course-of-conduct provision should not be used to bypass the three-part analysis required for acts committed by another person.
Can Conduct Underlying an Acquitted Charge Be Used?
Section 1B1.3(c) of the 2025 Guidelines Manual excludes conduct for which a defendant was charged and acquitted in federal court unless the same conduct also establishes, in whole or in part, the offense of conviction. This provision limits the use of qualifying acquitted conduct when calculating the guideline range.
The provision does not independently eliminate a sentencing court’s separate statutory authority under 18 U.S.C. § 3661 to receive and consider information concerning the background, character, and conduct of a person convicted of an offense.
The court must also identify the correct edition of the Guidelines Manual. Under § 1B1.11, the court applies the manual in effect on the sentencing date unless doing so would violate the Ex Post Facto Clause. If use of the sentencing-date manual creates that constitutional problem, the court applies the manual in effect when the offense of conviction was committed.
The 2025 Guidelines Manual took effect on November 1, 2025 and is the current published manual as of July 2026. That does not mean the 2025 manual applies to every pending case without the § 1B1.11 analysis.
What Evidence May Be Used to Calculate Drug Quantity?
Some federal drug prosecutions involve controlled substances that were seized, weighed, and tested. Other cases rely on estimates of transactions alleged to have occurred over an extended period.
Evidence may include controlled purchases, recorded calls, text messages, surveillance, financial records, shipping records, alleged drug ledgers, laboratory reports, photographs, witness testimony, and statements from alleged co-conspirators.
Section 2D1.1 permits a sentencing court to approximate quantity when no drugs were seized or when the amount seized does not reflect the alleged scale of the offense. The approximation must still rest on evidence possessing a sufficient level of reliability.
The government bears the burden of proving a disputed drug quantity by a preponderance of the evidence. The Sixth Circuit has also directed sentencing courts to identify the evidence supporting the quantity, make specific factual findings, and explain the method used to reach the final figure.
A quantity estimate may be challenged when it relies on unclear dates, inconsistent transaction amounts, unsupported assumptions about frequency, duplicate transactions, uncertain measurements, or statements lacking detail and corroboration.
Can a Cooperating Witness’s Estimate Be Used?
A statement from an informant, cooperating witness, or alleged co-conspirator may be considered in a drug-quantity calculation. The statement’s detail, consistency, source, and evidentiary support can become central issues.
A defense review may examine changes in the witness’s account, cooperation benefits, uncertain dates, memory problems, mathematical errors, lack of personal knowledge, conflicts with physical evidence, and the absence of supporting records.
In United States v. Hawkins, decided on January 20, 2026, the Sixth Circuit reviewed a presentence calculation attributing 3,414.62 grams of actual methamphetamine to the defendant. Much of the calculation relied on another person’s assertion that the defendant purchased 85 percent of his supply. The Sixth Circuit concluded that the disputed estimate lacked a sufficient evidentiary foundation, reversed the sentence, and remanded the case for resentencing.
The decision does not establish that a cooperating witness’s statement can never support a quantity finding. It shows that a disputed estimate must have enough detail and reliability to support the amount used at sentencing.
The Sixth Circuit reached a related conclusion in United States v. Histed. The district court did not explain the evidence or methodology supporting its selected drug quantity. The appellate court remanded for particularized findings and directed the lower court to identify the basis for the final figure.
How Multiple Controlled Substances Are Combined
A case involving more than one controlled substance may require conversion into a common reference called converted drug weight.
Under § 2D1.1, each substance is converted under the applicable table, and the resulting amounts are combined to identify the corresponding offense level. Converted drug weight is a guideline reference used for substances not directly listed at the relevant level and for cases involving different controlled substances.
Errors may arise from using the wrong substance, measurement, conversion factor, or transaction amount. The calculation may also depend on the form or purity of the substance identified by the evidence.
Methamphetamine allegations can present an additional issue because § 2D1.1 distinguishes between a methamphetamine mixture, methamphetamine actual, and “ice.” Laboratory testing, sample size, and the connection between a tested sample and other alleged transactions may affect the calculation.
A purity result from one sample does not automatically establish the classification or purity of every alleged transaction. The government must support the amount and classification it asks the court to use.
Challenging Drug Quantity in the Presentence Report
After a guilty plea or conviction, a United States probation officer may prepare a presentence investigation report, also called a PSR. The report addresses the offense, criminal history, applicable guideline calculations, personal background, and other information relevant to sentencing.
The PSR may contain a proposed drug-quantity calculation based on investigative reports, plea documents, trial evidence, laboratory records, witness accounts, or information supplied by prosecutors.
The inclusion of a quantity in the PSR does not prevent the defense from disputing it. A court may, however, accept undisputed PSR facts. A bare denial may not be enough to place a factual assertion in dispute.
An objection should identify the specific transaction, statement, estimate, conversion, date, or methodology being challenged. Supporting records or evidence may be used to question the reliability or accuracy of the proposed calculation. The government retains the burden of proving a disputed quantity by a preponderance of the evidence.
Federal presentence procedures provide a process for the parties to submit written objections, for probation to respond, and for unresolved issues to be presented to the sentencing court.
Possible objections may address transactions outside the scope of the defendant’s agreement, activity before the defendant joined, unreliable witness estimates, duplicate transactions, incorrect conversions, mathematical mistakes, unsupported purity findings, or a lack of defendant-specific findings.
Readers can also review how federal sentencing works and the role of evidence in federal criminal cases.
Questions That May Matter in a Drug-Quantity Dispute
A drug-quantity review may begin by identifying the activity the defendant agreed to undertake and the dates of the defendant’s alleged participation.
The analysis may then separate quantities connected to the defendant’s own conduct from quantities connected only to other participants. For conduct committed by another person, the court should examine scope, furtherance, and reasonable foreseeability.
The supporting evidence also matters. Physical evidence, laboratory reports, communications, shipping records, financial information, and witness testimony may be compared with the amount proposed in the PSR.
Other issues may include duplicate transactions, unsupported estimates, inconsistent witness accounts, incorrect drug conversions, unclear dates, and activity falling outside the defendant’s agreement.
The answers can affect the advisory guideline calculation and the sentencing arguments presented to the court. No particular result follows from raising a quantity dispute. The outcome depends on the charges, evidence, findings, applicable Guidelines Manual, and rulings in the individual case.
Speak With a Federal Drug Defense Attorney
Drug-quantity attribution can affect the advisory guideline range, statutory sentencing issues, plea discussions, and the defense position presented at sentencing.
A careful analysis may require review of the indictment, discovery, recorded communications, laboratory evidence, witness accounts, plea documents, verdict, and presentence report.
Davis & Hoss represents people facing federal criminal allegations. Learn more about the firm’s federal drug violations defense services or contact the office to discuss an investigation, indictment, plea, or sentencing issue.
Frequently Asked Questions
Can every drug in a conspiracy be attributed to every defendant?
No. For guideline purposes, another participant’s transaction must have been within the scope of the criminal activity the defendant agreed to undertake, in furtherance of that activity, and reasonably foreseeable in connection with it. A court should conduct an individualized analysis instead of assigning the complete conspiracy quantity without supporting findings.
Can drugs sold before a person joined the conspiracy be attributed to that person?
Under the jointly undertaken criminal activity rule, conduct committed before the defendant joined is not included as that defendant’s relevant conduct merely because the defendant later learned about it. The alleged joining date and the evidence supporting that date may become disputed issues.
Can a court estimate drug quantity when no drugs were seized?
Yes. Section 2D1.1 permits an approximation when no drugs were seized or when the amount seized does not reflect the alleged scale of the offense. The estimate must rest on sufficiently reliable evidence and be supported by a preponderance of the evidence.
Can text messages be used to establish drug quantity?
Text messages may be presented as evidence of transactions, prices, participants, frequency, or amounts. Their authorship, meaning, completeness, context, and connection to an actual controlled substance may be disputed.
Can a co-conspirator’s statement establish drug quantity?
A co-conspirator’s statement or testimony may support a quantity finding. Its detail, consistency, source, and evidentiary support matter. A disputed quantity should not rest on an unsupported allegation lacking enough information to support the calculation.
Can conduct underlying an acquitted federal charge be used as relevant conduct?
Under § 1B1.3(c) of the 2025 Guidelines Manual, conduct underlying a federal acquittal is excluded from relevant conduct unless the same conduct also establishes, in whole or in part, the offense of conviction. That rule concerns calculation of the guideline range. It does not independently resolve the information a court may consider under 18 U.S.C. § 3661, and the court must first identify the applicable Guidelines Manual under § 1B1.11.
This article discusses federal law and the Federal Sentencing Guidelines as reviewed in July 2026. It provides general legal information and is not legal advice. Reading this article does not create an attorney-client relationship.